United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial

United Therapeutics (NASDAQ: UTHR) announced Monday that a Phase 2/3 study testing dinutuximab (Unituxin) did not meet the main goal of helping patients live longer. The Silver Spring, MD-based company says full data from the study will be presented at upcoming scientific conferences and in peer-reviewed publications.